To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
Sponsor and status
114th Congress (2015–2017)
Enacted — Signed by the President on Nov 25, 2015
This bill was enacted after being signed by the President on November 25, 2015.
3 Cosponsors (2 Democrats, 1 Republican)
Position statements
What legislators are saying
“Green, Pitts, Pallone Introduce Legislation to Accelerate Approval for New Therapies”
—
Rep. Gene Green [D-TX29, 1993-2018]
(Co-sponsor)
on Feb 4, 2015
“On the House Floor This Week - 3/23/15”
—
Rep. John K. Delaney [D-MD6, 2013-2018]
on Mar 23, 2015
“Schrader Praises House Passage of Energy & Commerce Bills as a \"Bipartisan Victory\"”
—
Rep. Kurt Schrader [D-OR5, 2009-2022]
on Mar 16, 2015
Incorporated legislation
This bill incorporates provisions from:
S. 481: Improving Regulatory Transparency for New Medical Therapies Act
Ordered Reported on Sep 30, 2015. 100% incorporated. (compare text)
H.R. 2340: To amend the Controlled Substances Import and Export Act to remove regulatory barriers to the re-exportation of controlled substances among members of the European Economic Area.
Introduced on May 14, 2015. 79% incorporated. (compare text)
History
|
Jun 10, 2014
|
|
Earlier Version —
Ordered Reported
This activity took place on a related bill, H.R. 4299 (113th). |
|
Feb 2, 2015
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
|
Feb 11, 2015
|
|
Considered by House Committee on Energy and Commerce
A committee held a hearing or business meeting about the bill.
|
|
Mar 16, 2015
|
|
Passed House (Senate next)
The bill was passed in a vote in the House. It goes to the Senate next. The vote was by voice vote so no record of individual votes was made. |
|
Mar 16, 2015
|
|
Reported by House Committee on Energy and Commerce
A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions. |
|
Oct 26, 2015
|
|
Passed Senate with Changes (back to House)
The Senate passed the bill with changes not in the House version and sent it back to the House to approve the changes. The vote was by Unanimous Consent so no record of individual votes was made. |
|
Nov 16, 2015
|
|
House Agreed to Changes
The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill. The vote was without objection so no record of individual votes was made. |
|
Nov 25, 2015
|
|
Enacted — Signed by the President
The President signed the bill and it became law.
|
H.R. 639 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 639. This is the one from the 114th Congress.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 639 — 114th Congress: Improving Regulatory Transparency for New Medical Therapies Act.” www.GovTrack.us. 2015. February 4, 2023 <https://www.govtrack.us/congress/bills/114/hr639>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
